CVRx (NASDAQ:CVRX) Given New $13.00 Price Target at Cantor Fitzgerald

CVRx (NASDAQ:CVRX) had its price objective increased by Cantor Fitzgerald from $11.00 to $13.00 in a report issued on Thursday morning, MarketBeat reports. They currently have an overweight rating on the stock.

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of CVRx in a research report on Thursday, October 30th. One investment analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and two have issued a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $13.17.

CVRx Stock Performance

NASDAQ:CVRX traded down $0.34 during mid-day trading on Thursday, reaching $9.71. The stock had a trading volume of 370,914 shares, compared to its average volume of 292,047. CVRx has a twelve month low of $4.30 and a twelve month high of $18.55. The business has a 50 day simple moving average of $8.70 and a 200 day simple moving average of $7.52. The firm has a market capitalization of $253.94 million, a price-to-earnings ratio of -4.62 and a beta of 1.28. The company has a debt-to-equity ratio of 0.85, a quick ratio of 10.78 and a current ratio of 11.99.

CVRx (NASDAQ:CVRX) last posted its quarterly earnings results on Wednesday, November 5th. The company reported ($0.49) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.50) by $0.01. The firm had revenue of $14.69 million for the quarter, compared to the consensus estimate of $14.16 million. CVRx had a negative return on equity of 79.31% and a negative net margin of 95.61%. CVRx has set its Q4 2025 guidance at EPS. FY 2025 guidance at EPS. On average, analysts expect that CVRx will post -1.91 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of CVRX. Lord Abbett & CO. LLC purchased a new position in shares of CVRx in the 1st quarter worth $4,852,000. Parkman Healthcare Partners LLC lifted its stake in shares of CVRx by 33.5% in the 1st quarter. Parkman Healthcare Partners LLC now owns 1,229,522 shares of the company’s stock valued at $15,037,000 after purchasing an additional 308,348 shares in the last quarter. Balyasny Asset Management L.P. increased its position in CVRx by 65.5% during the 2nd quarter. Balyasny Asset Management L.P. now owns 674,685 shares of the company’s stock worth $3,967,000 after purchasing an additional 267,063 shares in the last quarter. Marshall Wace LLP increased its position in CVRx by 238.1% during the 2nd quarter. Marshall Wace LLP now owns 350,080 shares of the company’s stock worth $2,058,000 after purchasing an additional 246,548 shares in the last quarter. Finally, FourWorld Capital Management LLC raised its holdings in CVRx by 563.7% in the second quarter. FourWorld Capital Management LLC now owns 124,123 shares of the company’s stock valued at $730,000 after buying an additional 105,422 shares during the period. Institutional investors and hedge funds own 75.27% of the company’s stock.

About CVRx

CVRx, Inc, a commercial-stage medical device company, focuses on developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases. The company offers Barostim, a neuromodulation device indicated to improve symptoms for patients with heart failure with reduced ejection fraction or systolic heart failure.